TY - JOUR
T1 - Diagnostic Accuracy of Blood-Based Biomarker Panels
T2 - A Systematic Review
AU - Hardy-Sosa, Anette
AU - León-Arcia, Karen
AU - Llibre-Guerra, Jorge J.
AU - Berlanga-Acosta, Jorge
AU - Baez, Saiyet de la C.
AU - Guillen-Nieto, Gerardo
AU - Valdes-Sosa, Pedro A.
N1 - Funding Information:
We are thankful for the National Nature and Science Foundation of China (NSFC, grant 61871105) and CNS Program of UESTC (No. Y0301902610100201).
Publisher Copyright:
Copyright © 2022 Hardy-Sosa, León-Arcia, Llibre-Guerra, Berlanga-Acosta, Baez, Guillen-Nieto and Valdes-Sosa.
PY - 2022/3/11
Y1 - 2022/3/11
N2 - Background: Because of high prevalence of Alzheimer’s disease (AD) in low- and middle-income countries (LMICs), there is an urgent need for inexpensive and minimally invasive diagnostic tests to detect biomarkers in the earliest and asymptomatic stages of the disease. Blood-based biomarkers are predicted to have the most impact for use as a screening tool and predict the onset of AD, especially in LMICs. Furthermore, it has been suggested that panels of markers may perform better than single protein candidates. Methods: Medline/Pubmed was searched to identify current relevant studies published from January 2016 to December 2020. We included all full-text articles examining blood-based biomarkers as a set of protein markers or panels to aid in AD’s early diagnosis, prognosis, and characterization. Results: Seventy-six articles met the inclusion criteria for systematic review. Majority of the studies reported plasma and serum as the main source for biomarker determination in blood. Protein-based biomarker panels were reported to aid in AD diagnosis and prognosis with better accuracy than individual biomarkers. Conventional (amyloid-beta and tau) and neuroinflammatory biomarkers, such as amyloid beta-42, amyloid beta-40, total tau, phosphorylated tau-181, and other tau isoforms, were the most represented. We found the combination of amyloid beta-42/amyloid beta-40 ratio and APOEε4 status to be most represented with high accuracy for predicting amyloid beta-positron emission tomography status. Conclusion: Assessment of Alzheimer’s disease biomarkers in blood as a non-invasive and cost-effective alternative will potentially contribute to early diagnosis and improvement of therapeutic interventions. Given the heterogeneous nature of AD, combination of markers seems to perform better in the diagnosis and prognosis of the disease than individual biomarkers.
AB - Background: Because of high prevalence of Alzheimer’s disease (AD) in low- and middle-income countries (LMICs), there is an urgent need for inexpensive and minimally invasive diagnostic tests to detect biomarkers in the earliest and asymptomatic stages of the disease. Blood-based biomarkers are predicted to have the most impact for use as a screening tool and predict the onset of AD, especially in LMICs. Furthermore, it has been suggested that panels of markers may perform better than single protein candidates. Methods: Medline/Pubmed was searched to identify current relevant studies published from January 2016 to December 2020. We included all full-text articles examining blood-based biomarkers as a set of protein markers or panels to aid in AD’s early diagnosis, prognosis, and characterization. Results: Seventy-six articles met the inclusion criteria for systematic review. Majority of the studies reported plasma and serum as the main source for biomarker determination in blood. Protein-based biomarker panels were reported to aid in AD diagnosis and prognosis with better accuracy than individual biomarkers. Conventional (amyloid-beta and tau) and neuroinflammatory biomarkers, such as amyloid beta-42, amyloid beta-40, total tau, phosphorylated tau-181, and other tau isoforms, were the most represented. We found the combination of amyloid beta-42/amyloid beta-40 ratio and APOEε4 status to be most represented with high accuracy for predicting amyloid beta-positron emission tomography status. Conclusion: Assessment of Alzheimer’s disease biomarkers in blood as a non-invasive and cost-effective alternative will potentially contribute to early diagnosis and improvement of therapeutic interventions. Given the heterogeneous nature of AD, combination of markers seems to perform better in the diagnosis and prognosis of the disease than individual biomarkers.
KW - Alzheimer’s disease (AD)
KW - biomarker panel
KW - blood-based biomarker
KW - diagnosis
KW - preclinical AD
UR - http://www.scopus.com/inward/record.url?scp=85127667077&partnerID=8YFLogxK
U2 - 10.3389/fnagi.2022.683689
DO - 10.3389/fnagi.2022.683689
M3 - Article
C2 - 35360215
AN - SCOPUS:85127667077
SN - 1663-4365
VL - 14
JO - Frontiers in Aging Neuroscience
JF - Frontiers in Aging Neuroscience
M1 - 683689
ER -